CPDR001E2201 (NET): AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PDR001 IN PATIENTS WITH ADVANCED OR METASTATIC NON-FUNCTIONAL NEUROENDOCRINE TUMORS OF PANCREATIC, GASTROINTESTINAL (GI), OR THORACIC ORIGIN WHO HAVE PROGRESSED ON PRIOR TREATMENT. INCLUSIONS TERMINÉES DURANT LE 2ÈME SEMESTRE 2017
